|
Jul 1
|
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
|
|
Jun 27
|
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
|
|
Jun 26
|
Sector Update: Health Care Stocks Edge Higher Late Afternoon
|
|
Jun 26
|
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
|
|
Jun 25
|
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
|
|
Jun 12
|
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
|
|
Jun 3
|
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
|
|
Mar 10
|
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
|
|
Feb 16
|
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
|
|
Jul 9
|
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
|
|
Jul 9
|
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
|
|
Dec 20
|
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
|
|
Nov 8
|
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
|
|
Nov 6
|
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
|
|
Sep 22
|
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
|
|
Sep 21
|
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
|
|
Sep 19
|
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
|
|
Jun 29
|
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
|
|
Jun 28
|
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
|
|
Jun 26
|
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
|